Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 1062-1069

  Sonneveld, P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CEFOPERAZONE; CEFTRIAXONE; CHLOROQUINE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; DIPYRIDAMOLE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; NICARDIPINE; NIFEDIPINE; NIGULDIPINE; QUINIDINE; RAPAMYCIN; RHODAMINE 123; SDZ 280446; TACROLIMUS; TRIFLUOPERAZINE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCA ALKALOID; VINDOLINE; YOHIMBINE;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ACUTE DISEASE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; P-GLYCOPROTEIN;

EID: 0030003254     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00054-8     Document Type: Article

References (97)

1. Goldie JH, Goldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 1983, 67, 923-930.
2. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 2, 116-124.
3. Borst P. Genetic mechanisms of drug resistance. A review. Acta Oncologica 1991, 30, 87-105.
4. Lemontt JF, Azzaria M, Gros P. Increased MDR gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Res 1988, 48, 6348-6353.
5. Fojo AT, Whang-Peng J, Gottesmann MM, Pastan I. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1985, 82, 7661-7665.
6. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221, 1285-1288.
7. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993, 81, 2215-2222.
8. Nooter K, Herweijer H. Multidrug resistance (MDR) genes in human cancer. Br J Cancer 1991, 63, 663-669.
9. Pileri SA, Sabattini E, Falini B, et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991, 19, 131-140.
10. Niehans GA, Jaszcz W, Brunetto V, et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse, large cell and immunoblastic lymphomas. Cancer Res 1992, 52, 3768-3775.
11. Schlaifer D, Laurent G, Chittal S, et al. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br J Cancer 1990, 62, 177-182.
12. Miller RL, Bukowski RM, Budd GT, et al. Clinical modulation doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol 1988, 6, 880-888.
13. Dan S, Esumi M, Sawada U, et al. Expression of a multidrug resistance gene in human malignant lymphomas and related disorders. Leuk Res 1991, 15, 1139-1143.
14. Rodriguez C, Gommes T, Robert J, Rossi JF. Expression of P-glycoprotein and anoinic glutathione S-transferase genes in non-Hodgkin's lymphoma. Leuk Res 1993, 17, 149.
15. Chen AL, Su IJ, Chen YC, Lee TC, Wang CH. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunopheno-types, and other predisposing factors. J Clin Oncol 1993, 11, 109-115.
16. Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994, 12, 2453-2459.
17. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesmann MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84, 265-269.
18. Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 1989, 165, 1415-1421.
19. Sato H, Gottesmann MM, Goldstein LJ, et al. Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res 1990, 14, 11-21.
20. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 1991, 77, 50-53.
21. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991, 78, 586-592.
22. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991, 83, 708-712.
23. Zhou DC, Marie JP, Suberville AM, Zittoun R. Relevance of MDR1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992, 6, 879-885.
24. Gekeler V, Frese G, Noller R, et al. MDR1/P-glycoprotein, topo-isomerase, and glutatione-S-transferase π gene expression in primary and relapsed acute adult and childhood leukaemias. Br J Cancer 1992, 66, 507-517.
25. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 1992, 79, 473-476.
26. Te Boekhorst PAW, De Leeuw K, Schoester M, et al. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ leukemia cells. Blood 1993, 82, 3157-3162.
27. Ino T, Miyazaki H, Tsogai M, et al. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia 1994, 8, 1492-1497.
28. Lamy T, Goasguen JE, Mordelet E, et al. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994, 8, 1879-1883.
29. - cases. Blood 1995, 86, 2329-2342.
30. Paietta E, Andersen J, Racevskis J, et al. Multidrug resistance gene (MDR1) transcript or CD34 antigen expression levels do not predict for complete remissions in de novo adult acute myeloid leukemia (AML): an Eastern Cooperative Oncology Group study. Blood 1994, 84, 3771 (abstract).
31. Te Boekhorst PAW, Löwenberg B, van Kapel J, Nooter K, Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995, 9, 1025-1031.
32. List A, Spier CM, Cline A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991, 78, 28-34.
33. Campos L, Guyotat D, Jaffar C, Solary E, Archimbaud E, Treille D. Correlation of MDR1/P170 expression with daunorubicin uptake and sensitivity of leukemia progenitors in acute myeloid leukemia. Eur J Haematol 1992, 48, 254-258.
34. Drenou B, Fardel O, Amiot L, Fauchet R. Detection of P-glycoprotein activity on normal and leukemic CD34+ cells. Leuk Res 1993, 17, 1031-1035.
35. Marie JP, Bastie JN, Colana F, et al. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 1993, 7, 821-824.
36. Ludescher C, Thaler J, Drach D, et al. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 1992, 82, 161-168.
37. Sonneveld P, Nooter K. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol 1990, 75, 208-210.
38. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991, 78, 44-50.
39. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992, 79, 3267-3273.
40. Chan H, Thorner P, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990, 8, 689-704.
41. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989, 74, 913-917.
42. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989, 7, 415-424.
43. Dalton WS, Grogan T, Rybski J, et al. Immunohistochemical detection and quantitation of P-glycoprotein in drug-resistant human multiple myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989, 73, 747-752.
44. Sonneveld P, Schoester M, De Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma. J Clin Oncol 1994, 12, 1584-1591.
45. Cornelissen J, Sonneveld P, Schoester M, et al. MDR-1 expression and response to vincristine, doxorubicin and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 1994, 12, 115-119.
46. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993, 81, 490-495.
47. Guerci A, Merlin HL, Missoun N, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995, 85, 2147-2153.
48. Leith CP, Kopecky KJ, Chen IM, et al. MDR1 expression is highly predictive for achievement of complete remission (CR) in acute myeloid leukemia (AML) in the elderly: a Southwest Oncology Group study. Blood 1995, 86, 286a (abstract).
49. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of the novo acute lymphoblastic leukemia: prognostic implications. Blood 1993, 81, 2394-2398.
50. Miwa H, Kenchiki K, Norihisa M, et al. Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 1993, 82, 3445-3451.
51. Burger H, Nooter K, Sonneveld P, Van Wingerden KE, Zaman GJR, Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol 1994, 88, 348-356.
52. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 1994, 8, 2163-2168.
53. Schneider E, Cowan KH, Bader H, et al. Increased expression of the multidrug resistance-associated protein gene in relapsed leukemia. Blood 1995, 85, 186-190.
54. Slapak CA, Mizunuma N, Kufe DW. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 1994, 84, 3113-3121.
55. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995, 1, 81-93.
56. Kuss BJ, Deeley RG, Cole SPC, et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994, 343, 1531-1534.
57. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993, 53, 1475-1479.
58. List AF, Spier CS, Abbaszadegan M, et al. Non-P-glycoprotein (Pgp) mediated multidrug resistance (MDR): identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia. Blood 1993, 82 (Suppl 10), 443a.
59. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T, Parmiani G. Modulation of multidrug resistance by verapamil or MDR1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 1990, 46, 727-732.
60. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992, 80, 2735-2739.
61. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 1990, 50, 1748-1756.
62. Beck WT. Multidrug resistance and its circumvention. Eur J Cancer 1990, 26, 513-515.
63. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 1988, 33, 454-462.
64. Fisher GA, Sikic BJ. Clinical studies with modulators of multidrug resistance (Review). Hematol-Oncol Clin N Am 1995, 9, 363-382.
65. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991, 77, 348-354.
66. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium channel antagonists and calmodulin inhibitors. Cancer Res 1983, 43, 2267-2271.
67. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and vinblastine. Cancer Res 1984, 44, 4303-4307.
68. Twentyman PR. A possible role for Cyclosporins in cancer chemotherapy. Anticancer Res 1988, 8, 983-993.
69. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of MDR1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporin. J Natl Cancer Inst 1990, 28, 1133-1140.
70. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Overexpression of the MDR1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 1990, 45, 263-268.
71. Ross DD, Wooten PJ, Tong Y, et al. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremaphor EL. Blood 1994, 83, 1337-1347.
72. Ross DD, Wooten PJ, Sridhara R, Ordónez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993, 82, 1288-1299.
73. Osann K, Sweet P, Slater LM. Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cell lines in vitro. Cancer Chemother Pharmacol 1992, 230, 152-154.
74. Solary E, Bidan JM, Calvo F, et al. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukemia and myeloma. Leukemia 1991, 5, 592-597.
75. Marie JP, Helou C, Thevenin D, Delmer A, Zittoun R. In vitro effect of P-glycoprotein (Pgp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML). Exp Hematol 1992, 20, 565-568.
76. Visani G, Fogli M, Tosi P, et al. Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors. Ann Haematol 1993, 66, 273-276.
77. Chao NJ, Aihara M, Blume KG, Sikic BI. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporin in multidrug-resistant human leukemic cell lines and normal bone marrow. Exp Hematol 1990, 18, 1193-1198.
78. Aihara A, Sikic BI, Blume KG, Chao NJ. Assessment of purging with multidrug resistance (MDR) modulators and VP-16: results of long-term marrow culture. Exp Hematol 1990, 18, 940-944.
79. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991, 9, 17-24.
80. Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987, 5, 641-647.
81. Jones RD, Kerr DJ, Harnett AN, Rankin EM, Ray S, Kaye SB. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 1990, 62, 133-135.
82. Solary E, Caillot D, Chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992, 10, 1730-1736.
83. Cairo MS, Siegel S, Anas N, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 1989, 49, 1063-1066.
84. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. Natl Cancer Inst 1992, 84, 1811-1816.
85. Philip PA, Joel S, Monkman SC, et al. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 1992, 65, 267-270.
86. Boesch D, Gaveriaux C, Jachez B, et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991, 27, 1639-1642.
87. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992, 80, 2729-2734.
88. Kerr DJ, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986, 18, 239-242.
89. Linn SC, Van Kalken CK, Van Tellingen O, et al. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 1994, 12, 812-819.
90. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 1994, 11, 1652-1660.
91. Sonneveld P, Dune BGM, Lokhorst HM, et al. Modulation of multidrug resistant multiple myeloma by Cyclosporin. Lancet 1992, 340, 255-259.
92. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992, 10, 1635-1642.
93. Durie BG, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988, 68, 203-206.
94. Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator Dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995, 13, 1985-1994.
95. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13, 1995-2004.
96. Dalton WS, Crowley JJ, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995, 75, 815-820.
97. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlation with treatment outcome and MDR1 expression. Leukemia 1993, 7, 825-831.